Galapagos NV (AMS:GLPG)
26.84
+0.30 (1.13%)
Nov 24, 2025, 5:35 PM CET
Galapagos NV Revenue
Galapagos NV had revenue of 71.16M EUR in the quarter ending September 30, 2025, with 18.90% growth. This brings the company's revenue in the last twelve months to 286.92M, up 10.31% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
286.92M
Revenue Growth
+10.31%
P/S Ratio
6.10
Revenue / Employee
407.56K
Employees
704
Market Cap
1.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
| Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
| Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
| Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGalapagos NV News
- 17 days ago - RBC Capital Raises Price Target for GLPG to $32. ... - GuruFocus
- 18 days ago - Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Galapagos NV (GLPG) Q3 2025 Earnings Call Highlights: Navigating Strategic Shifts Amidst ... - GuruFocus
- 18 days ago - Q3 2025 Galapagos NV Earnings Call Transcript - GuruFocus
- 18 days ago - Galapagos NV 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 21 days ago - Galapagos to Present New Data from Cell Therapy Program at ASH 2025 - GlobeNewsWire
- 26 days ago - GLPG Crosses Above Average Analyst Target - Nasdaq
- 4 weeks ago - Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors - GlobeNewsWire